Belldegrun Arie — SEC Form 4 filings
SEC reporting owner CIK 1296549. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-24.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-31 to 2026-06-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 2 filings — 2,057,470 shares, $9,999,992 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 23.
- Largest priced transaction: purchase of 1,724,137 shares @ $2.90 ($4,999,997) in Allogene Therapeutics, Inc., filed 2024-05-20.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | Director | 3 | 1 leg · 1,724,137 sh · $4,999,997 | — | 5 |
| LB PHARMACEUTICALS INC (LBRX) | 10% owner | 1 | 2 legs · 333,333 sh · $4,999,995 | — | 4 |
| Kronos Bio, Inc. (KRON) | Director | 2 | — | — | 7 |
| Ginkgo Bioworks Holdings, Inc. (DNA) | Director | 1 | — | — | 4 |
| UroGen Pharma Ltd. (URGN) | Director | 3 | — | — | 3 |
Form 4 filings — Belldegrun Arie
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-24 | 4 | UroGen Pharma Ltd. (URGN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-02-04 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 929,913 (derivative) @ $0 · Grant/award (A): 263,033 (derivative) @ $0 | EDGAR |
| 2025-09-16 | 4 | LB PHARMACEUTICALS INC (LBRX) jointly with Vida Ventures GP III, L.L.C., Vida Ventures III, L.P., Vida Ventures III-A, L.P., Vida Ventures Management Co. LLC | Conversion (C): 547,648 · Conversion (C): 1,262 · Purchase (P): 332,566 @ $15 · Purchase (P): 767 @ $15 · Conversion (C): 13,302,666 (derivative) @ $0 · Conversion (C): 30,667 (derivative) @ $0 | EDGAR |
| 2025-08-27 | 4 | UroGen Pharma Ltd. (URGN) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-20 | 4 | Kronos Bio, Inc. (KRON) | Code (U): 2,765,314 @ $0.57 · Code (U): 679,575 @ $0.57 · Disposition to issuer (D): 20,600 (derivative) @ $0 · Disposition to issuer (D): 34,000 (derivative) @ $0 · Disposition to issuer (D): 34,000 (derivative) @ $0 · Disposition to issuer (D): 34,000 (derivative) @ $0 | EDGAR |
| 2024-08-08 | 4 | UroGen Pharma Ltd. (URGN) | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-06-26 | 4 | Kronos Bio, Inc. (KRON) | Grant/award (A): 34,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Ginkgo Bioworks Holdings, Inc. (DNA) | Option exercise (M): 105,263 · Option exercise (M): 105,263 (derivative) · Grant/award (A): 432,900 (derivative) @ $0 · Grant/award (A): 571,428 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 344,828 @ $2.90 · Purchase (P): 1,724,137 @ $2.90 | EDGAR |
| 2024-01-31 | 4 | Allogene Therapeutics, Inc. (ALLO) | Grant/award (A): 211,973 @ $0 · Grant/award (A): 749,398 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1296549 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →